The Impact of State AIDS Drug Assistance Policies on Clinical and Economic Outcomes of People With HIV. (June 2016)

• Record Type: Journal Article
• Authors: Snider, Julia Thornton; Goldman, Dana P.; Rosenblatt, Lisa; Seekins, Daniel; Juday, Timothy; Sanchez, Yuri; Wu, Yanyu; Peneva, Desi; Romley, John A.
• Is Part Of: Medical care research and review. Volume 73:Number 3(2016:Jun.)
• Page Start: 329
• Page End: 348
• Publication Date: 2016-06
• Subjects: HIV and AIDS -- access to care -- state policy -- government policy -- low income; Medical care -- United States -- Periodicals; Medical care -- Periodicals; Medical care -- Research -- United States -- Periodicals; Medical care -- Research -- Periodicals; Medical economics -- United States -- Periodicals; Medical economics -- Periodicals; 362.10973
• DOI: 10.1177/1077558715614479
• Languages: English
• ISSNs: 1077-5587

Abstract

We investigated the effect of changes to state AIDS Drug Assistance Programs (ADAP) policies, which govern access to antiretroviral therapy (ART), on clinical and economic outcomes among low-income people living with HIV/AIDS. Retrospective analyses of ART access were conducted on state ADAP policies, using data from ADAP Monitoring Reports and Kaiser Family Foundation from 2006 to 2010. We found stricter eligibility requirements reduce the number of HIV-positive individuals with ART access through ADAP, and decreased ART use increases mortality by 2.67 quality-adjusted life years (QALYs) per beneficiary. If the ADAP income eligibility cutoff were decreased by 50 percentage points in each state, 4, 626 individuals would lose ART access nationwide. Based on a $22, 143 cost/QALY, this policy would save $274 million in health care expenditures (2012 dollars), but result in 12, 352 QALYs lost, valued at $1.2 billion. Therefore, states should exercise caution in restricting programs that increase ART access for low-income people living with HIV/AIDS.